Neuraxpharm

>£500m



Jamieson is delighted to announce that it has advised the Management team of Neuraxpharm on the sale of the business to Permira.

“It was a pleasure to see how competent and proactive we have been advised by the Jamieson team, at the same time maintaining our fast pace and delivering viable solutions.”

Dr. Jörg-Thomas Dierks, CEO

Stuart Coventry, Felix Rose, Jose Basabe, Laura Yell and Sabrina Goetz advised the Management team on their reinvestment into the new structure and the economic and legal terms and conditions of the management incentive plan going forwards.

With its unique understanding of the CNS market built over 35 years, Neuraxpharm is a leading and rapidly growing European speciality pharmaceutical company focused on the treatment of central nervous system disorders (CNS).